London, UK / New York, USA – A groundbreaking collaborative study has unveiled a critical connection between the natural process of ageing and the aggressive progression of cancer. Researchers from the Francis Crick Institute, UCL, Gustave Roussy, and Memorial Sloan Kettering Cancer Center (MSK) have discovered that age-related mutations in blood stem cells, a phenomenon known as Clonal Haematopoiesis of Indeterminate Potential (CHIP), can infiltrate cancerous tumours. This infiltration, termed Tumour Infiltrating Clonal Haematopoiesis (TI-CH), is not merely a bystander effect but is directly associated with significantly worse outcomes for patients across a range of cancer types.
The findings, published today in the prestigious New England Journal of Medicine, represent a significant leap in understanding the complex interplay between ageing, the immune system, and cancer evolution. The research highlights a novel mechanism by which the ageing process can actively fuel tumour growth and metastasis, offering crucial insights for the development of new diagnostic tools and targeted therapies to combat aggressive cancers.
The Main Facts: An Unseen Driver of Cancer Aggression Uncovered
For decades, scientists have grappled with the intricate relationship between advancing age and increased cancer risk and severity. While it has been understood that ageing leads to an accumulation of genetic changes, the precise mechanisms by which these age-related alterations influence solid tumours have remained largely elusive. This new research illuminates one such mechanism with profound implications.
The core discovery centres on Clonal Haematopoiesis of Indeterminate Potential (CHIP), a condition where blood stem cells acquire mutations and expand clonally over time. This phenomenon is remarkably common, affecting more than 10% of individuals over 65 years old, and its prevalence increases with age. While previously linked to an elevated risk of age-related disorders such as cardiovascular disease, CHIP’s direct impact on the evolution and prognosis of solid cancers had not been thoroughly investigated until now.
The collaborative team found that CHIP-mutated blood cells don’t just circulate in the bloodstream; they actively infiltrate the tumour microenvironment. This presence of mutated blood cells within the tumour, dubbed Tumour Infiltrating Clonal Haematopoiesis (TI-CH), was identified in a significant proportion of cancer patients with CHIP. Crucially, the study demonstrated that it is the presence of TI-CH within the tumour, rather than CHIP in the blood alone, that is an independent and robust predictor of a shorter survival time, increased risk of cancer relapse, and ultimately, cancer-related death.
This finding suggests that certain age-related immune cells, once thought to be primarily involved in general inflammatory responses, can be co-opted by tumours to create a more hospitable environment for their growth and spread. Specifically, the researchers identified an expansion of myeloid cells – a type of immune cell – within tumours infiltrated by CHIP mutations, particularly those affecting the TET2 gene. These myeloid cells, under the influence of the TET2 mutation, appear to remodel the tumour’s surroundings, accelerating its progression.
Chronology of a Groundbreaking Investigation
The journey to this discovery began with a compelling hypothesis: could age-related genetic changes in blood cells, known to influence systemic inflammation and other age-related diseases, also play a role in the progression of solid tumours? To answer this, the research team embarked on a multi-stage investigation, leveraging vast patient cohorts and advanced analytical techniques.
Initial Clues from Lung Cancer Patients
The initial phase of the study focused on a cohort of over 400 patients with lung cancer, primarily drawn from two seminal Cancer Research UK-funded studies: TRACERx (Tracking Cancer Evolution through therapy) and PEACE (Post-mortem Exome Analysis of Cancer Evolution). These studies provided invaluable longitudinal data and tissue samples, allowing for a deep dive into the genetic landscape of both the patients’ blood and their tumours.
Researchers first analysed blood samples from these patients to determine the presence of CHIP mutations. When this genetic data was correlated with clinical outcomes, a striking pattern emerged: patients with CHIP mutations in their blood exhibited a statistically significant association with shorter overall survival. This observation held true regardless of the patient’s age at diagnosis or the stage of their cancer, suggesting CHIP was an independent prognostic factor. This initial finding, while significant, begged a deeper question: how exactly were these blood mutations impacting the tumour?
Unveiling Tumour Infiltrating Clonal Haematopoiesis (TI-CH)
The next critical step was to investigate whether the CHIP mutations observed in the blood were merely a systemic marker or if the mutant blood cells were physically interacting with the tumours. Using sophisticated genetic sequencing techniques, the team meticulously examined lung tumour samples from patients who had CHIP. They discovered that in a substantial 42% of patients with CHIP, the very same mutations were present within their lung tumours. This phenomenon was termed Tumour Infiltrating Clonal Haematopoiesis, or TI-CH.
This distinction proved pivotal. The researchers found that it was the presence of TI-CH – the infiltration of CHIP-mutated cells directly into the tumour microenvironment – and not CHIP in the blood alone, that was associated with the greater risk of cancer relapse and, tragically, cancer-related death. This indicated a direct functional role for these mutated cells within the tumour itself.
Post-Mortem Validation: The PEACE Study’s Contribution
To further solidify these findings and explore the implications for metastatic disease – the primary cause of cancer death – the team turned to samples from the PEACE study. This unique post-mortem investigation provided a rare opportunity to analyse multiple metastatic sites where cancer had spread throughout the body. The analysis of these metastatic tumours corroborated the earlier findings, revealing that they frequently contained TI-CH mutations. This provided compelling evidence that TI-CH is not just present in primary tumours but also accompanies cancer as it spreads, potentially facilitating its dissemination and resistance to therapy.
Supporting Data: Mechanisms and Broader Impact
The discovery of TI-CH and its prognostic significance naturally led to an exploration of the underlying biological mechanisms. How do these age-related mutant blood cells, once inside a tumour, contribute to its aggression?
The Role of Myeloid Cells in the Tumour Microenvironment
The investigation into the cellular composition of lung tumours provided crucial answers. Researchers observed that patients with TI-CH exhibited a notable expansion of myeloid cells within their tumours. Myeloid cells are a diverse group of immune cells that play multifaceted roles in the body’s defence system, including inflammation, tissue repair, and immunity. However, within the complex milieu of a tumour, their role can be dual-edged.
Unlike certain immune cells, such as cytotoxic T-cells, which are primed to recognise and eliminate cancer cells, myeloid cells have been shown to regulate inflammation and can, paradoxically, support tumour progression and spread. Their presence can create an immunosuppressive environment, shield cancer cells from immune attack, and even promote angiogenesis (the formation of new blood vessels that feed the tumour). The expansion of these pro-tumourigenic myeloid cells in the context of TI-CH offered a compelling mechanistic link to the observed worse patient outcomes.
The Critical Influence of TET2 Mutations
Delving deeper, the team investigated specific genetic mutations within the CHIP framework. They discovered that when mutations affected a gene called TET2, these mutant blood cells were particularly prone to infiltrating tumours. The TET2 gene is a crucial regulator of blood cell production and function, playing a key role in epigenetic modifications that control gene expression. Disruptions to TET2 can lead to abnormal proliferation and differentiation of blood cells.
Using advanced single-cell analysis on hundreds of individual cells from the tumours of two patients with TI-CH, the researchers precisely mapped the location of TET2 mutations. This meticulous analysis confirmed that the TET2 mutations were predominantly found within myeloid cells, and not in other immune cell types, further solidifying the link between TET2-mutated myeloid cells and the tumour microenvironment.
To establish a causal link, the team collaborated with experts in blood cancer and CHIP at the Crick, led by Dominique Bonnet. They conducted experimental studies using organoids – miniature, lab-grown lung tumours that mimic the complexity of human tumours. When these organoids were co-cultured with TET2 mutant myeloid cells, the results were striking. The TET2 mutant myeloid cells actively remodelled the tumour microenvironment, creating conditions that significantly accelerated the growth of the tumour organoids. This experimental validation provided powerful evidence that TET2-mutated myeloid cells directly contribute to tumour progression.
Global Validation Across Diverse Cancer Types
The final, and perhaps most impactful, stage of the study involved a massive validation effort in collaboration with Memorial Sloan Kettering Cancer Center in the United States. Leveraging an unprecedented dataset of over 49,000 patients with a wide array of different cancer types, the team sought to determine if their findings from lung cancer were generalisable.
The results were unequivocal: across this vast and diverse cohort, the presence of TI-CH remained an independent predictor of shorter survival. This robust validation underscores the broad relevance of TI-CH as a prognostic factor across oncology. Furthermore, the study revealed that the prevalence of CHIP and TI-CH varied significantly between cancer types. These mutations were found to be more common in cancers notoriously difficult to treat, such as lung cancer, head and neck cancer, and pancreatic cancer. This observation suggests that TI-CH might be a particularly insidious factor in the most aggressive and resistant forms of the disease.
Official Responses: Perspectives from the Frontline of Research
The publication of these findings has generated considerable excitement within the scientific and clinical communities, offering new avenues for understanding and combating cancer.
Oriol Pich, a Postdoctoral Project Research Scientist in the Crick’s Cancer Evolution and Genome Instability Laboratory and a lead author of the study, emphasized the immediate practical implications of the discovery. "Our results show that blood cells carrying age-related mutations can infiltrate tumours and impact cancer evolution, leading to worse outcomes for patients," Pich stated. "This is important because CHIP is a natural phenomenon of ageing that is common in patients with cancer. Recognizing its role provides a new lens through which to view cancer progression, particularly in an ageing population." His remarks highlight the ubiquity of CHIP among cancer patients, suggesting that this phenomenon might be silently contributing to disease severity in a large proportion of cases.
Professor Charlie Swanton, Deputy Clinical Director at the Crick, Chief Clinician at Cancer Research UK, and Chief Investigator for TRACERx, underscored the novelty and significance of the interaction observed. "This is the first time that we’ve been able to see at scale, the interaction of two different types of ‘clonal proliferations’ – age-related CHIP and cancer," he explained. "This provides crucial insight into how ageing might impact cancer risk and progression, extending beyond simply the accumulation of tumour-specific mutations."
Professor Swanton further articulated the long-term vision stemming from this research. "As we start to piece together the picture of the most important mutations which evolve during the ageing process in cells from the bone marrow, and the impact they have in disease, we hope we can start to identify opportunities for intervention and maybe even prevention of some age-related cancers," he added. This statement points towards a future where understanding age-related biological changes could open doors to entirely new strategies for cancer prevention and treatment.
The collaborative nature of this extensive research, supported by Cancer Research UK, the National Institute of Health and Care Research UCLH Biomedical Research Centre, and other funders, speaks to the complex and multidisciplinary effort required to unravel such intricate biological puzzles.
Implications: A New Era in Cancer Understanding and Treatment
The discovery of Tumour Infiltrating Clonal Haematopoiesis (TI-CH) and its profound impact on cancer prognosis marks a significant turning point, opening up several critical implications for future research, patient care, and public health strategies.
For Patients: Improved Risk Stratification and Tailored Therapies
One of the most immediate implications is the potential for improved risk stratification. Identifying patients with CHIP and, more specifically, TI-CH, could allow clinicians to pinpoint individuals at higher risk for aggressive cancer relapse and shorter survival. This knowledge could inform more intensive monitoring schedules, earlier intervention strategies, or the selection of more aggressive upfront treatments for those patients. For instance, a patient with a seemingly early-stage cancer might be treated more aggressively if they also present with TI-CH, given the heightened risk.
Furthermore, the mechanistic insights gained, particularly regarding the role of TET2 mutant myeloid cells, open avenues for novel therapeutic targets. Future research could explore drugs that specifically target these pro-tumourigenic myeloid cells, neutralise their inflammatory signals, or modulate the TET2 pathway to prevent their detrimental infiltration and activity within the tumour microenvironment. Such targeted therapies could represent a new class of precision medicine, specifically designed to counteract the age-related drivers of cancer aggression.
For Research: Unravelling the Complex Crosstalk
The study provides a robust foundation for extensive future research. The immediate next steps, as highlighted by the researchers, will be to definitively confirm that CHIP directly contributes to cancer outcomes and to detail the exact molecular and cellular mechanisms by which CHIP is functionally implicated in the development of aggressive cancers. This will involve:
- Longitudinal Studies: Following patients with CHIP over extended periods to observe the development of TI-CH and its impact on disease progression.
- Interventional Studies: Investigating whether mitigating CHIP-related inflammation or targeting specific mutated myeloid cells can improve cancer outcomes in pre-clinical models and eventually in clinical trials.
- Broader Mechanistic Studies: Exploring other CHIP-related mutations beyond TET2 and their diverse effects on the tumour microenvironment.
- Interaction with Existing Therapies: Understanding how TI-CH influences responses to standard treatments, including chemotherapy, radiotherapy, and immunotherapies. For example, does TI-CH create an environment that makes tumours less responsive to checkpoint inhibitors?
This research also underscores the critical importance of understanding the tumour microenvironment – the complex ecosystem of cells, blood vessels, and signalling molecules surrounding a tumour. By demonstrating how age-related immune cells can profoundly reshape this environment, the study paves the way for a more holistic approach to cancer research that considers not just the cancer cells themselves, but also their interactions with the host.
For Public Health: A Holistic View of Ageing and Disease
In an increasingly ageing global population, the prevalence of age-related conditions like CHIP is on the rise. This study reinforces the interconnectedness of "diseases of ageing." Understanding how CHIP contributes to both cardiovascular disease and aggressive cancers paints a more comprehensive picture of health risks associated with ageing.
In the long term, this research might inform public health strategies related to ageing and cancer prevention. Could routine screening for CHIP become a part of comprehensive health assessments for older adults, allowing for early identification of individuals at higher risk for certain aggressive cancers? While such screening would require careful consideration of ethical implications, patient anxiety, and the availability of effective interventions, the potential for early risk stratification is substantial.
The findings also highlight the need for continued investment in research that bridges the gap between fundamental biological processes, such as ageing, and complex diseases like cancer. By understanding the intricate dance between our bodies’ natural changes and disease progression, we move closer to a future where age is not just a risk factor, but a pathway to targeted prevention and cure.
About the Author
